Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Conditions
Interventions
RO7297089
Locations
10
Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
LIVERPOOL HOSPITAL; HAEMATOLOGY; Ingham Institute for Medical Research
Liverpool, New South Wales, Australia
Royal Adelaide Hospital; Haematology Clinical Trials
Adelaide, South Australia, Australia
St. Vincent's Hospital Melbourne
Fitzroy, South Australia, Australia
Peter Mac Callum Cancer Center
East Melbourne, Victoria, Australia
UZ Gent
Ghent, Belgium
Start Date
July 8, 2020
Primary Completion Date
February 23, 2022
Completion Date
February 23, 2022
Last Updated
July 3, 2024
NCT04973605
NCT06138275
NCT05862012
NCT06285318
NCT07391657
NCT07284758
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions